WO1993014107A1 - Process for preparing 3-acylestratrienes and acylbenzenes - Google Patents

Process for preparing 3-acylestratrienes and acylbenzenes Download PDF

Info

Publication number
WO1993014107A1
WO1993014107A1 PCT/US1993/000078 US9300078W WO9314107A1 WO 1993014107 A1 WO1993014107 A1 WO 1993014107A1 US 9300078 W US9300078 W US 9300078W WO 9314107 A1 WO9314107 A1 WO 9314107A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
benzo
formula
reaction
triene
Prior art date
Application number
PCT/US1993/000078
Other languages
English (en)
French (fr)
Inventor
Neil Howard Baine
Michael Mcguire
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP5512541A priority Critical patent/JPH07503008A/ja
Priority to SK801-94A priority patent/SK80194A3/sk
Priority to BR9305707A priority patent/BR9305707A/pt
Priority to EP93902956A priority patent/EP0621866A4/en
Priority to CA002127274A priority patent/CA2127274A1/en
Priority to KR1019940702342A priority patent/KR940704064A/ko
Publication of WO1993014107A1 publication Critical patent/WO1993014107A1/en
Priority to FI943213A priority patent/FI943213A0/fi
Priority to NO942531A priority patent/NO942531L/no
Priority to BG98888A priority patent/BG98888A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10NELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10N30/00Piezoelectric or electrostrictive devices
    • H10N30/20Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Definitions

  • the present invention relates to an improved process for the preparation of substituted steroidal benzo esters and substituted steroidal benzo acids.
  • Such compounds are described in U.S. Patent Nos. 4,954,446; 4,937,237; 4,970,205 and 4,882,319 as being useful for or preparing compounds which are useful for inhibiting steroid 5- ⁇ -reductase.
  • said steroidal trifluoromethyl sulfonate intermediate has been reacted in metal-catalyzed coupling reactions in the presence of various coupling reagents (followed by an optional, if applicable hydrolysis reaction) to form the corresponding steroidal benzo esters and the corresponding steroidal benzo acids in U.S. Patent Nos. 4,937,237 and 4,882,319.
  • This invention relates to an improved process for converting phenols to benzo esters and benzo acids.
  • This invention relates to an improved process for converting steroidal phenols to steroidal benzo esters and steroidal benzo acids.
  • This invention specifically relates to an improved process for the preparation of 17Ji-(N-t- butylcarboxamide)-estr-1,3,5(10)-triene-3-carboxylic acid and hydrates thereof.
  • the present invention provides a process for the production of a benzo acid or a benzo ester which comprises reacting a phenol with fluorosulfonic anhydride and a base, preferably a tertiaryamine base such as triethylamine, pyridine or tributylamine in an appropriate solvent to form a benzo fluorosulfonate compound and subsequently reacting said benzo fluorosulfonate compound in a metal-catalyzed coupling reaction in the presence of an appropriate coupling reagent followed by an optional, if applicable hydrolysis reaction.
  • a phenol with fluorosulfonic anhydride and a base preferably a tertiaryamine base such as triethylamine, pyridine or tributylamine in an appropriate solvent to form a benzo fluorosulfonate compound and subsequently reacting said benzo fluorosulfonate compound in a metal-catalyzed coupling reaction in the presence of an appropriate coupling reagent
  • the present invention specifically provides a process for the production of a compound of Formula (I)
  • R3 and R 4 are each independently selected form hydrogen, C3_gcycloalkyl, phenyl; or R3 and R 4 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or moieties which are chemically conterible to moieties of (i) and
  • R* is an acid or ester; or a pharmaceutically acceptable salt, hydrate of solvate thereof, which comprises reacting a compound of the Formula (II)
  • reaction to convert Formula II compounds to formula III is preformed at a temperature from -78°C to 20°C, particularly preferred temperature range is from -10 to 10°C.
  • reaction to convert Formula III compounds to Formula I compounds is preferred at a temperature of 25°C to 100°C a particular preferred temperature range is from 50 to 90°C.
  • Compounds of Formula I comprise R-- or moieties which can be chemically converted to those of R 1 by known chemical reactions such as described in J. Fried and J. Edwards, Organic Reactions in Steroid Chem stry, Pub: Van Nostrand Reinhold Company (1972) provided that R 1 does not include any such moieties that render inoperative the presently invented process.
  • Reactions to convert said moieties to R-- are performed on products of the synthetic pathways disclosed or claimed herein or, where appropriate or preferable on certain intermediates in these synthetic pathways.
  • carboxylic acid substituents can be converted to the carboxamide by conversion to the acid halide followed by reacting the same with an amine.
  • Carboxylate substituents can be converted to the acid and treated as above.
  • Nitriles can be converted to the carboxamide by reaction with an alkylating agent, such as t- butylacetate or t-butanol under acidic catalysis.
  • C ] __ n alkyl means a straight or branched hydrocarbon chain having 1 to n carbons.
  • R 1 is (i) H and CONR 3 R 4 , where R 3 and R 4 are each independently selected from hydrogen, C3_gcycloalkyl, phenyl; or R ⁇ and R 4 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; or moieties which are chemically convertible to moieties of (i) .
  • metal-catalyzed coupling reaction is meant that the prepared fluorosulfonated compound is reacted in a suitable organic solvent, preferably a dimethylsulfoxide-Ci-gOH solution (when an ester is desired) or toluene, dimethylformamide or THF (when an acid is desired) with a base, preferably a tertiaryamine base such as triethylamine, pyridine or tributylamine, a phosphine such as bis (diphenylphosphino)alkane, preferably 1,3 bis(diphenylphosphino)propane or tri-o-tolylphosphine, or a C]__galKOH, and a metal catalyst, preferably a palladium catalyst such as palladium (II) acetate, palladium (II) chloride and bis (triphenylphosphine) palladium II acetate, and a coupling rea
  • a suitable organic solvent preferably
  • coupling reagent as used herein is meant a compound which is capable of reacting with an aryl radical to form an acid or an ester.
  • Preferred coupling reagents which when added to the metal- catalyzed coupling reaction, as described herein, yield preferred acid and ester groups, as disclosed herein, are carbon monoxide (to yield -COOH) , ethyltributylstannyl acetate (to yield -CH2COOH) , dimethyl phosphite (to yield -P(0) (OH)2) and hypophosphorous acid crystals (to yield -PH(O)OH).
  • phenol as used herein is meant a hydroxylated six membered aromatic ring, unsubstituted or substituted with non reactive substituents, said aromatic ring may also be part of a polycyclic molecule such as a naphthyl or steroidal moleucle, said molecule being unsubstituted or substituted with non reactive substituents.
  • acid as used herein is meant any group which is capable of acting as a proton donor including but not limited to; -COOH, -P(0) (OH)2, -PH(0)OH, -SO3H and -(CH2) 1-3-COOH.
  • esters as used herein is meant a group consisting of an acid, as defined above, in which the donatable proton or protons are replaced by alkyl substituents.
  • steroidal benzo as used herein is meant a steroid with an aromatic A ring.
  • solvent an organic solvent such as methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran (THF) , ethyl ether, toluene, ethyl acetate, dimethylsulfoxide, methanol or dimethylforamide.
  • organic solvent such as methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran (THF) , ethyl ether, toluene, ethyl acetate, dimethylsulfoxide, methanol or dimethylforamide.
  • the base utilized to prepare compounds of Formula II is triethylamine.
  • the solvent utilized to prepare compounds of Formula II is methylene chloride.
  • the catalyst utilized in said metal catalyzed coupling reaction is palladium (II) acetate.
  • Preferred acids used to describe R-- in Formula (I) include; -COOH, -P(0) (0H) 2 , -PH(0)OH, -SO3H, and - (CH2) ⁇ -C00H. Particularly preferred among the above acids is -COOH.
  • the present invention is usuful for the conversion of phenols to benzo esters and benzo acids.
  • a preferred aspect of the invention is the conversion of steroidal phenols to steroidal benzo esters and steroidal benzo acids.
  • the process of the present invention is particularly useful for preparing a compound of Structure IIIA.
  • Carbon monoxide is available from Matheson Gas Products (E. Rutherford, NJ) .
  • a vessel was charged with dimethylsulfoxide (1350 mL) , methanol (75 mL, 5.4 molar equivalents), 3- fluorosulphonylestra-1, 3,5(10)-triene-17 ⁇ -N-t- butylcarboxamide (150 g, 1 molar equivalent) , triethylamine (76.3 g, 2.2 molar equivalents), and 1,3- bis(diphenylphosphino)propane (1.41 g, 0.01 molar equivalent) . The mixture was stirred until a solution was obtained. Palladium acetate (0.768 g, 0.01 molar equivalent) was added and the flask was filled and evacuated with carbon monoxide three times.
  • the vessel was pressurized with 7 psi carbon monoxide and the reaction was stirred rapidly.
  • the reaction solution was heated to 75°C.
  • the carbon monoxide uptake was finished in about 1.5 hours.
  • the reaction was cooled to 15°C and stirred for 2 hours.
  • the solid product was isolated by suction filtration, and the mother liquors were used to rinse out the inside of the reactor.
  • the solid product was thoroughly washed with water (1.5 L) and dried under vacuum at 95°C to afford pure methyl 17 ⁇ -(N-tert- butylcarboxamide)-estra-1,3,5(10)-triene-3-carboxylate C116.4 g) in 85% yield, mp 155-157°C.
  • 17 ⁇ -(N-tert-Butylcarboxamide)-estra-1, 3, 5 (10)- triene-3-carboxylic acid is a compound which is currently undergoing clinical investigation for the- treatment of benign prostatic hypertrophy. The isolation of anhydrous and hydrated forms of said compound is necessary in order to establish an optimal and reproducible bioavailability profile for said compound.
  • a vessel was charged with 5 volumes of dimethylformamide, 3-fluorosulphonylestra-l,3,5 (10)- triene-17 ⁇ -N-t-butylcarboxamide (1 molar equivalent, prepared as described in Example 1C) , tri-n-butylamine (4.5 molar equivalents), formic acid (2 molar equivalents) and bis (triphenylphosphine)palladium acetate (0.02 molar equivalents) .
  • the flask was evacuated and filled with carbon monoxide three times.
  • the vessel was pressurized with 7 psi carbon monoxide and the reaction was stirred rapidly.
  • the reaction solution was heated to 75°C until the uptake of carbon monoxide was complete.
  • the reaction was cooled to room temperature.
  • Zinc Chloride (1.91 g, 1.4 molar equivalents) was weighed into a 200 mL flask fitted with a stir bar and serum cap. The mixture was heated to 150°C under vacuum (1.0 mm) for 1 hour. The flask was cooled to 25°C and the vacuum was broken with argon. 3- Fluorosulphonylestra-1,3,5 (10)-triene-17 ⁇ -N-t- butylcarboxamide (4.38 g, 1 molar equivalent, prepared as described in Example 1C) , ethyltributylstannyl acetate (5.28 g, 1.4 molar equivalents), and dimethylformamide ( 20.0 mL) were added to the flask.
  • the flask was evacuated and flushed with argon three times. Tri-o-tolyl ⁇ hosphine (0.091 g, 0.03 molar equivalent) and palladium acetate (0.045 g, 0.02 molar equivalent) were added and the reaction vessel was evacuated and flushed with argon three times. The mixture was heated for 1.0 hour at 80°C. Toluene (100 mL) and water (100 mL) were added and the mixture was stirred for 5 minutes. The mixture was filtered through celite and poured into a separatory funnel. The aqueous layer was separated and discarded. The organic phase was washed again with water (100 mL) .
  • the organic phase was washed with saturated sodium fluoride (2 x 50 mL) and filtered through celite after each wash.
  • the organic phase was washed with water (2 x 50 mL) , dried over sodium sulfate, filtered and concentrated under vacuum.
  • the product was isolated as a thick oil.
  • the color of the reaction solution went from light yellow to red/black. After 1.0 hour the reaction was cooled to 23°C. The reaction mixture was poured into water (50 mL) and the mixture was extracted with methylene chloride (50 mL) . The methylene chloride layer was extracted with water (50 mL) three times and was dried over magnesium sulfate and filtered. The solvent was removed under vacuum. The crude product was purified by bulb to bulb distillation to yield methyl benzoate (0.62 gram) as a colorless oil.
  • a vessel was charged with 5 volumes of dimethylformamide, phenylfluorosulphonate (1 molar equivalent, prepared as described in Example 4A) , tri-n- butylamine (4.5 molar equivalents), formic acid (2 molar equivalents) and bis (triphenylphosphine)-palladium acetate (0.02 molar equivalents) .
  • the flask was evacuated and filled with carbon monoxide three times.
  • the vessel was pressurized with 7 psi carbon monoxide and the reaction was stirred rapidly.
  • the reaction solution was heated to 75°C until the uptake of carbon monoxide was complete.
  • the reaction was cooled to room temperature. Ethyl acetate and water were added, and the organic layer was separated.
  • the organic phase was washed with water and dried over magnesium sulfate.
  • the organic phase was concentrated under vacuum to yield a crude benzoic acid which was purified by silica chromatography (hexane/ethyl
  • the mixture was evacuated and flushed with carbon monoxide.
  • the mixture was heated to 65°C for two hours under a slight positive carbon monoxide pressure.
  • the mixture was poured into water (50 mL) and was extracted with methylene chloride (3 x 50 mL) .
  • the methylene chloride layers were combined and extracted with water (2 x 100 mL) .
  • the methylene chloride layer was dried over magnesium sulfate and filtered. The solvent was removed under vacuum to afford methyl-3, 5-dimethylbenzoate, 0.750 g, as a colorless oil.
  • Example 7 17 ⁇ - (N-tert-Bntylcarboxamide) -estra-1.3. (10)-triene-3- carboxyiic acid. (anhydrous and hydrated)
  • a solution of 3-hydroxypyridine (1 molar equivalent) and triethylamine (2.5 molar equivalents) in methylene chloride was cooled to -5°C and treated with fluorosulfonic anhydride (1.3 molar equivalents) while maintaining the temperature between -5 and 0°C. After stirring for one hour the reaction was quenched with water (100 mL) . The organic phase was separated, washed with water (100 mL) , and dried over magnesium sulfate. The solution was concentrated under vacuum to afford pyridine-3-fluorosulfonate as a crude colorless oil.
  • the methylene chloride layer was extracted with water (50 mL) three times and was dried over magnesium sulfate and filtered. The solvent was removed under vacuum. The crude product was purified by silica gel chromatography to yield methyl nicotinate as a crystals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/US1993/000078 1992-01-06 1993-01-06 Process for preparing 3-acylestratrienes and acylbenzenes WO1993014107A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP5512541A JPH07503008A (ja) 1992-01-06 1993-01-06 3−アシルエストラトリエンおよびアシルベンゼンの製造方法
SK801-94A SK80194A3 (en) 1992-01-06 1993-01-06 Process for preparing 3-acylestratrienes and acylbenzenes
BR9305707A BR9305707A (pt) 1992-01-06 1993-01-06 Processo para preparaçao de 3-acilestratrienos e acilbenzenos
EP93902956A EP0621866A4 (en) 1992-01-06 1993-01-06 Process for preparing 3-acylestratrienes and acylbenzenes.
CA002127274A CA2127274A1 (en) 1992-01-06 1993-01-06 Process for preparing 3-acylestratrienes and acylbenzenes
KR1019940702342A KR940704064A (ko) 1992-01-06 1993-01-06 3-아실에스트라트리엔 및 아실벤젠을 제조하는 방법(Process for preparing 3-acylestratrienes and acylbenzenes)
FI943213A FI943213A0 (fi) 1992-01-06 1994-07-05 Prosessi valmistaa 3-asyyliestratrieenejä ja asyylibentseenejä
NO942531A NO942531L (no) 1992-01-06 1994-07-05 Fremgangsmåte for fremstilling av 3-acylöstratriener og acylbenzener
BG98888A BG98888A (en) 1992-01-06 1994-07-05 Method for the preparation of 3-acylestratrienes and acylbezenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81718092A 1992-01-06 1992-01-06
US07/817,180 1992-01-06

Publications (1)

Publication Number Publication Date
WO1993014107A1 true WO1993014107A1 (en) 1993-07-22

Family

ID=25222515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000078 WO1993014107A1 (en) 1992-01-06 1993-01-06 Process for preparing 3-acylestratrienes and acylbenzenes

Country Status (21)

Country Link
EP (1) EP0621866A4 (xx)
JP (1) JPH07503008A (xx)
KR (1) KR940704064A (xx)
CN (1) CN1077200A (xx)
AP (1) AP361A (xx)
AU (1) AU3434793A (xx)
BG (1) BG98888A (xx)
BR (1) BR9305707A (xx)
CA (1) CA2127274A1 (xx)
FI (1) FI943213A0 (xx)
HU (1) HUT67566A (xx)
IL (1) IL104303A0 (xx)
MA (1) MA22762A1 (xx)
MX (1) MX9300026A (xx)
NO (1) NO942531L (xx)
OA (1) OA09959A (xx)
RU (1) RU94037761A (xx)
SI (1) SI9300005A (xx)
SK (1) SK80194A3 (xx)
WO (1) WO1993014107A1 (xx)
ZA (1) ZA938B (xx)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033761A1 (en) * 1994-06-03 1995-12-14 Smithkline Beecham Corporation Steroid derivatives for treatment of 5 alpha reductase
US5618806A (en) * 1992-04-30 1997-04-08 Smithkline Beecham Corporation 17α and 17β-substituted estra-1,3,5(10)-triene-3-carbboxlic acid
WO1997040062A1 (en) * 1996-04-18 1997-10-30 Pharmacia & Upjohn S.P.A. Process for preparing steroids having a carboxamide side-chain
US6262043B1 (en) 1999-04-13 2001-07-17 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10),16-tetraene derivatives
US20140114088A1 (en) * 2011-06-29 2014-04-24 Central Glass Company, Limited Process for Producing Fluorosulfuric Acid Aromatic-Ring Esters
JP2017524731A (ja) * 2014-06-06 2017-08-31 ザ スクリプス リサーチ インスティテュート フッ化硫黄(vi)化合物およびそれの製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4954446A (en) * 1988-05-25 1990-09-04 Smithkline Beecham Corporation Aromatic steroid 5-α-reductase inhibitors
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954446A (en) * 1988-05-25 1990-09-04 Smithkline Beecham Corporation Aromatic steroid 5-α-reductase inhibitors
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELSCHEMBROICHI et al., Organometallic, 2nd Ed., C. Weinheim, Germany, VCH, 1992, pp. 412-415. *
ROTH et al., L. Organic Chemistry, 1991, 56, 3493-3496, "Palladium Cross-Coupling Reactions of Aryl Fluoro-Sulfonates. An Alternative to Triflate Chemistry", see page 3494, column 1 and page 3496. *
See also references of EP0621866A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618806A (en) * 1992-04-30 1997-04-08 Smithkline Beecham Corporation 17α and 17β-substituted estra-1,3,5(10)-triene-3-carbboxlic acid
WO1995033761A1 (en) * 1994-06-03 1995-12-14 Smithkline Beecham Corporation Steroid derivatives for treatment of 5 alpha reductase
WO1997040062A1 (en) * 1996-04-18 1997-10-30 Pharmacia & Upjohn S.P.A. Process for preparing steroids having a carboxamide side-chain
US6262043B1 (en) 1999-04-13 2001-07-17 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10),16-tetraene derivatives
US6638923B2 (en) 1999-04-13 2003-10-28 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10),16-tetraene derivatives
US20140114088A1 (en) * 2011-06-29 2014-04-24 Central Glass Company, Limited Process for Producing Fluorosulfuric Acid Aromatic-Ring Esters
EP2727905A1 (en) * 2011-06-29 2014-05-07 Central Glass Company, Limited Process for producing fluorosulfuric acid aromatic-ring esters
EP2727905A4 (en) * 2011-06-29 2015-03-25 Central Glass Co Ltd PROCESS FOR THE PRODUCTION OF AROMATIC CYCLIC ESTERS OF FLUOROSULFURIC ACID
US9040745B2 (en) * 2011-06-29 2015-05-26 Central Glass Company, Limited Process for producing fluorosulfuric acid aromatic-ring esters
JP2017524731A (ja) * 2014-06-06 2017-08-31 ザ スクリプス リサーチ インスティテュート フッ化硫黄(vi)化合物およびそれの製造方法
US10765645B2 (en) 2014-06-06 2020-09-08 The Scripps Research Institute Sulfur(VI) fluoride compounds and methods for the preparation thereof
JP2023075089A (ja) * 2014-06-06 2023-05-30 ザ スクリプス リサーチ インスティテュート フッ化硫黄(vi)化合物およびそれの製造方法

Also Published As

Publication number Publication date
SI9300005A (en) 1993-09-30
NO942531D0 (no) 1994-07-05
CA2127274A1 (en) 1993-07-22
MA22762A1 (fr) 1993-10-01
OA09959A (en) 1995-12-11
BR9305707A (pt) 1996-12-31
HUT67566A (en) 1995-04-28
NO942531L (no) 1994-07-05
EP0621866A4 (en) 1996-03-20
FI943213A (fi) 1994-07-05
HU9402029D0 (en) 1994-09-28
FI943213A0 (fi) 1994-07-05
MX9300026A (es) 1993-12-01
AP361A (en) 1994-09-09
JPH07503008A (ja) 1995-03-30
RU94037761A (ru) 1997-05-27
ZA938B (en) 1994-06-16
BG98888A (en) 1995-05-31
AU3434793A (en) 1993-08-03
KR940704064A (ko) 1994-12-12
AP9300474A0 (en) 1993-01-31
SK80194A3 (en) 1994-12-07
CN1077200A (zh) 1993-10-13
EP0621866A1 (en) 1994-11-02
IL104303A0 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
JP7365082B2 (ja) Baを原料とするウルソデオキシコール酸の合成方法
AU615439B2 (en) Steroid 5-alpha-reductase inhibitors
AU2012331996B2 (en) Ulipristal acetate preparation method and intermediate thereof
EP0298652B1 (en) Dehydrogenation process and intermediates
US5116983A (en) Dehydrogenation process intermediates
AP361A (en) Process for the preparation of substituted steroidal benzo esters and acids.
JPH0378394B2 (xx)
AU2004218221C1 (en) Process for the production of tibolone
JPH04288096A (ja) 3−オキソ−4−アザ−アンドロスト−1−エン 17β−ケトンの新製造方法
JP2001233854A (ja) N−ヒドロキシ環状イミドの製造方法
JP4015206B2 (ja) メドロゲストンの製造
WO2015114518A2 (en) Procedure for the preparation of abiraterone acetate and intermediates thereof
PL118827B1 (en) Method of manufacture of tricyclicdiketone
JPH06501272A (ja) 17β−置換−4−アザ−5α−アンドロスタン−3−オン誘導体の製法
CN113968888B (zh) 一种胆甾衍生物的制备方法、其中间体及应用
WO1993016098A1 (en) Process of preparing 3-acylandrostadienes
JP5075629B2 (ja) エストロンおよび/またはエストラジオール誘導体の調製方法
US4723045A (en) Processes for preparing cholesta-1,5,7-trien-3-ol
CN107011138B (zh) 一种西他列汀中间体的制备方法
JP2002533334A (ja) 抗ヒスタミン活性を有する三環式化合物を調製するためのプロセス
EP0866798B1 (en) Preparation of ester derivatives of steroids
US4108851A (en) 3β,17-Dihydroxy-5α,17α-pregn-20-ene-21-carboxylic acid γ-lactone and esters thereof
TWI570131B (zh) 製備17-經取代類固醇之方法
JP2016527213A (ja) アビラテロン酢酸エステルの製造方法
Penov Gaši et al. Improved methods for obtaining immonium perchlorates and enamines of solanidine type steroidal alkaloids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 2127274

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 246787

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 80194

Country of ref document: SK

Ref document number: PV1994-1623

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 943213

Country of ref document: FI

Ref document number: 94-01145

Country of ref document: RO

ENP Entry into the national phase

Ref document number: 1994 256285

Country of ref document: US

Date of ref document: 19940706

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1993902956

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993902956

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: PV1994-1623

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1993902956

Country of ref document: EP